uniQure N.V. (NASDAQ:QURE – Get Free Report)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $20.97, but opened at $21.94. uniQure shares last traded at $21.8710, with a volume of 256,843 shares trading hands.
Analysts Set New Price Targets
A number of research analysts recently issued reports on QURE shares. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Leerink Partners upped their price target on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Finally, William Blair upgraded shares of uniQure to a “strong-buy” rating in a research report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.25.
Check Out Our Latest Research Report on QURE
uniQure Price Performance
uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the firm posted ($0.69) EPS. On average, analysts anticipate that uniQure N.V. will post -3.82 EPS for the current year.
Institutional Trading of uniQure
Institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new stake in uniQure during the second quarter valued at $15,254. IFP Advisors Inc grew its stake in shares of uniQure by 39.8% in the 2nd quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 791 shares in the last quarter. Stephens Inc. AR acquired a new position in uniQure in the first quarter worth approximately $182,000. Cannon Global Investment Management LLC acquired a new position in uniQure in the first quarter worth approximately $199,000. Finally, Rangeley Capital LLC raised its position in uniQure by 52.9% during the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 4,500 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.
About uniQure
uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.
uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.
Featured Articles
- Five stocks we like better than uniQure
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
